原发灶不明转移癌基因表达谱分析技术进展

doi:10.11904/j.issn.1002-3070.2017.06.014

Abstract

Abstract: Primary lesions unknown metastatic cancer (CUP)is a class of histopathologically confirmed metastases.However,a variety of clinical diagnosis and treatment can not clear the primary tumor.The identification of tumor primary site is the first step in the diagnosis of CUP.The histopathology,immunohistochemistry and PET /CT are commonly used clinical diagnosis and treatment.Gene expression profiling technique is a new method for the diagnosis of primary tumor in recent years.It has high diagnostic accuracy,sensitivity and specificity,and is expected to achieve individual treatment of patients with CUP.

Key words: Cancer of unknown primary sites(CUP), Gene expression profiling(GEP), Progress in diagnosis

CLC Number:

HAN Qian, LIN Lianjun, LIU Xinmin. Advances in gene expression profiling of metastases from unidentified primary tumor[J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(6): 554-558.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2017.06.014

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2017/V31/I6/554

References

1 National Comprehensive Cancer Network.Clinical Practice Guidelines in Oncology.Occult primary(cancer of unknown primary[CUP]),version 2.2016[M/OL].https://www.nccn.org/professionals/physician_gls/f_guidelines.asp,2016.
2 Greco FA.Cancer of unknown primary site:still an entity,a biological mystery and a metastatic model[J].Nat Rev Cancer,2014,14(1):3-4.
3 Hainsworth JD,Greco FA.Gene expression profiling in patients with carcinoma of unknown primary site:from translational research to standard of care[J].Virchows Arch,2014,464(4):393-402.
4 Wang G,Wu Y,Zhang W,et al.Clinical value of whole-body ¹⁸F fluorodeoxyglucose positron emission tomography/computed tomography in patients with carcinoma of unknown primary[J].J Med Imaging Radiat Oncol,2013,57(1):65-71.
5 Riaz S,Nawaz MK,Faruqui ZS,et al.Diagnostic accuracy of ¹⁸F-fluorodeoxyglucose positron emission tomography-computed tomography in the evaluation of carcinoma of unknown primary[J].Mol Imaging Radionucl Ther,2016,25(1):11-18.
6 Hemminki K,Liu H,Heminki A,et al.Power and limits of modern cancer diagnostics:cancer of unknown primary[J].Ann Oncol,2012,23(3):760-764.
7 Burglin SA,Hess S,Hoilund-carlsen PF,et al.¹⁸F-FDG PET/CT for detection of the primary tumor in adults with extracervical metastases from cancer of unknown primary:A systematic review and meta-analysis[J].Medicine,2017,96(16):e6713.
8 Varadhachary GR,Raber MN.Cancer of unknown primary site[J].N Engl J Med,2014,371(8):757-765.
9 Pentheroudakis G,Spector Y,Krikelis D,et al.Global microRNA profiling in favorable prognosis subgroups of cancer of unknown primary(CUP)demonstrates no significant expression differences with metastases of matched known primary tumors[J].Clin Exp Metastasis,2013,30(4):431-439.
10 Ma XJ,Patel R,Wang X,et al.Molecular classification of human cancers using a 92-gene real-time quantitative polymerase chain reaction assay[J].Arch Pathol Lab Med,2006,130(4):465-473.
11 Tothill RW,Shi F,Paiman L,et al.Development and validation of a gene expression tumour classifier for cancer of unknown primary[J].Pathology,2015,47(1):7-12.
12 Brachtel EF,Operana TN,Suillivan PS,et al.Molecular classification of cancer with the 92-gene assay in cytology and limited tissue samples[J].Oncotarget,2016,7(19):27220-27231.
13 Monzon FA,Lyons-weiler M,Buturovic LJ,et al.Multicenter validation of a 1,550-gene expression profile for identification of tumor tissue of origin[J].J Clin Oncol,2009,27(15):2503-2508.
14 Horlings HM,Vanlaar RK,Kerst JM,et al.Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary[J].J Clin Oncol,2008,26(27):4435-4441.
15 Rosenfeld N,Aharonov R,Meiri E,et al.MicroRNAs accurately identify cancer tissue origin[J].Nat Biotechnol,2008,26(4):462-469.
16 Solilde R,Vincent M,Moller AK,et al.Efficient identification of miRNAs for classification of tumor origin[J].J Mol Diagn,2014,16(1):106-115.
17 Ferracin M,Pedriali M,Veronese A,et al.MicroRNA profiling for the identification of cancers with unknown primary tissue-of-origin[J].J Pathol,2011,225(1):43-53.
18 Meiri E,Mueller WC,Rosenwald S,et al.A second-generation microRNA-based assay for diagnosing tumor tissue origin[J].The Oncologist,2012,17(6):801-8012.
19 Pentheroueakis G,Pavlidis N,Fountzilas G,et al.Novel microRNA-based assay demonstrates 92% agreement with diagnosis based on clinicopathologic and management data in a cohort of patients with carcinoma of unknown primary[J].Mol Cancer,2013,12(57):1-8.
20 Moran S,Arribas C,Esteller M.Validation of a DNA methylation microarray for 850,000 CpG sites of the human genome enriched in enhancer sequences[J].Epigenomics,2016,8(3):389-399.
21 Elizabeth M,Matthew LZ,Yang ZH,et al.A multiplexed marker-based algorithm for diagnosis of carcinoma of unknown primary using circulating tumor cells[J].Oncotarget,2015,7(4):15.
22 Economopoulou P,Mountzios G,Pavlidis N,et al.Cancer of unknown primary origin in the genomic era: Elucidating the dark box of cancer[J].Cancer Treat Rev,2015,41(7):598-604.
23 Handorf CR,Kulkarni A,Grenert JP,et al.A multicenter study directly comparing the diagnostic accuracy of gene expression profiling and immunohistochemistry for primary site identification in metastatic tumors[J].Am J Surg Pathol,2013,37(7):1067-1075.
24 Greco FA,Lennington WJ,Spigel DR,et al.Poorly differentiated neoplasms of unknown primary site:diagnostic usefulness of a molecular cancer classifier assay[J].Mol Diagn Ther,2015,19(2):91-97.
25 Weiss LM,Chu P,Schroeder BE,et al.Blinded comparator study of immunohistochemical analysis versus a 92-gene cancer classifier in the diagnosis of the primary site in metastatic tumors[J].J Mol Diagn,2013,15(2):263-269.
26 Greco FA,Lennington WJ,Spigel DR,et al.Molecular profiling diagnosis in unknown primary cancer:accuracy and ability to complement standard pathology[J].J Natl Cancer Inst,2013,105(11):782-790.
27 Kerr SE,Schnabel CA,Sullivan PS,et al.A 92-gene cancer classifier predicts the site of origin for neuroendocrine tumors[J].Mod Pathol,2014,27(1):44-54.
28 Kerr SE,Schabel CA,Sullivan PS,et al.Multisite validation study to determine performance characteristics of a 92-gene molecular cancer classifier[J].Clin Cancer Res,2012,18(14):3952-3960.
29 Loffler H,Pfarr N,Kriegsmann M,et al.Molecular driver alterations and their clinical relevance in cancer of unknown primary site[J].Oncotarget,2016,7(28):44322-44329.
30 Ross JS,Wang K,Gay L,et al.Comprehensive genomic profiling of carcinoma of unknown primary site:new routes to targeted therapies[J].JAMA Oncol,2015,1(1):40-49.
31 Gatalica Z,Millis SZ,Vranic S,et al.Comprehensive tumor profiling identifies numerous biomarkers of drug response in cancers of unknown primary site:Analysis of 1806 cases[J].Oncotarget,2014,5(23):12440-12447.
32 Ali SM,Sanford EM,Klempner SJ,et al.Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies[J].Oncologist,2015,20(5):499-507.
33 Varadhachary G.Carcinoma of unknown primary site:the poster child for personalized medicine? [J].JAMA Oncol,2015,1(1):19-21.
34 Kamposioras K,Pentheroudakis G,Pavlidis N.Exploring the biology of cancer of unknown primary:breakthroughs and drawbacks[J].Eur J Clin Invest,2013,43(5):491-500.
35 Nystrom SJ,Hornberger JC,Varadhachary GR,et al.Clinical utility of gene-expression profiling for tumor-site origin in patients with metastatic or poorly differentiated cancer:impact on diagnosis,treatment,and survival[J].Oncotarget,2012,3(6):620-628.
36 Hainsworth JD,Schnabel CA,Erlander MG,et al.A retrospective study of treatment outcomes in patients with carcinoma of unknown primary site and a colorectal cancer molecular profile[J].Clin Colorectal Cancer,2012,11(2):112-118.
37 Hainsworth JD,Rubin MS,Spigel DR,et al.Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site:a prospective trial of the Sarah Cannon research institute[J].J Clin Oncol,2013,31(2):217-223.
38 Gross-goupil M,Massard C,Lesimple T,et al.Identifying the primary site using gene expression profiling in patients with carcinoma of an unknown primary(CUP):a feasibility study from the GEFCAPI[J].Oncologie,2012,35(1/2):54-55.
39 Le Tourneau C,Delord JP,Goncalves A,et al.Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer(SHIVA):a multicentre,open-label,proof-of-concept,randomised,controlled phase 2 trial[J].Lancet Oncol,2015,16(13):1324-1334.
40 Yoon HH,Foster NR,Meyers JP,et al.Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin,paclitaxel,and everolimus:NCCTG N0871(alliance)[J].Ann Oncol,2016,27(2):339-344.
41 National Cancer Institute.Molecular profiling-based assignment of cancer therapy for patients with advanced solid tumors[DB/OL].https://clinicaltrials.gov/ct2/show/NCT01827384?term=NCT01827384&rank=1,2017.
42 Anderson Cancer Center.Randomized study evaluating molecular profiling and targeted agents in metastatic cancer[DB/OL].https://clinicaltrials.gov/ct2/show/NCT0215
2254?term=IMPACT2&rank=4,2017.
43 Gustave Roussy,Cancer Campus,Grand Paris.Trial comparing a strategy based on molecular analysis to the empiric strategy in patients sith CUP[DB/OL].https://clinicaltrials.gov/ct2/show/NCT01540058?term=GEFCAPI04&rank=1,2017.
44 Hannouf MB,Winquist E,Mahmud SM,et al.Cost-effectiveness of using a gene expression profiling test to aid in identifying the primary tumour in patients with cancer of unknown primary[J].Pharmacogenomics J,2017,17(3):286-300.

[1]	LI Ji, CHEN Yang, ZHANG Maorong, YANG Zhao, TANG Xian, WEN Hongmei. Analysis of proportion and trend prediction of disability-adjusted life years attributed to aging population in common digestive system malignant tumors in China [J]. Journal of Practical Oncology, 2025, 39(5): 372-380.
[2]	ZHOU Suxia, XU Zhihua, GUO Shuling, FAN Ning, XU Lili. Analysis for the prevalence trend of malignant tumor incidence and mortality in cancer registration areas in Qinghai Province from 2014 to 2021 [J]. Journal of Practical Oncology, 2025, 39(5): 381-387.
[3]	REN Fanghan, ZHU Tiancen, LI Yanxia, CHEN Lili, NA Jun, TIAN Yuanmeng, MU Huijuan. Analysis of the incidence and mortality of lymphoma in cancer registration areas of Liaoning Province from 2016 to 2020 and their changing trends [J]. Journal of Practical Oncology, 2025, 39(5): 388-392.
[4]	LIU Lu, ZHU Jiahe, WANG Jia, ZHANG Bolun, XING Dehao, DING Gaoheng, WEI Xingmin, LIU Yuqin. Prediction analysis of incidence trend and age-period-cohort model of esophageal cancer in cancer registration areas of Gansu Province from 2010 to 2021 [J]. Journal of Practical Oncology, 2025, 39(5): 393-399.
[5]	LIU Yang, WANG Ying, MA Xiang, SONG JiaBao, LIU DaMin, CHEN Lili. Analysis of incidence and mortality of malignant tumors among urban residents in Yingkou City,Liaoning Province in 2021 [J]. Journal of Practical Oncology, 2025, 39(5): 400-404.
[6]	LI Yun, SHI Pinghui. Analysis of gastroscopic screening and follow-up results among high-risk populations for gastric cancer in Gejiu City,Yunnan Province [J]. Journal of Practical Oncology, 2025, 39(5): 405-411.
[7]	LI Yifan, QIN Chuanyu, ZENG Xi, LU Yajiao, LIAO Guangdong, KANG Leni, YANG Ying, ZHOU Min, XI Mingrong, YANG Chunxia, LI Jing. Analysis of the acceptance and influencing factors of self-collection urine HPV testing in cervical cancer screening [J]. Journal of Practical Oncology, 2025, 39(5): 412-417.
[8]	LI Xudong, LIU Tong. The single cell transcriptome sequencing reveals the role and prognostic value of PCLAF and ERO1A in the progression of breast cancer [J]. Journal of Practical Oncology, 2025, 39(5): 418-427.
[9]	ZHANG Xuan, LI Juan, FANG Chuanfeng, TIAN Hong, LIU Jiaren. Research progress of phytochemicals in tumor immunotherapy [J]. Journal of Practical Oncology, 2025, 39(5): 428-432.
[10]	XIN Xin, XIONG Wenjing, ZHANG Chunnuan, LI Xiaojing, GAO Xue, ZHANG Yue. Lactylation modification:an emerging target in cancer therapy [J]. Journal of Practical Oncology, 2025, 39(5): 433-436.
[11]	ZHOU Qing, WANG Yamei. Research progress on epigenetic regulation mechanism of oral adenoid cystic carcinoma [J]. Journal of Practical Oncology, 2025, 39(5): 437-444.
[12]	LUO Qiyuan, SHAO Hongchao, ZHOU Shaohua, YE Mushi. The current research status and prospect of the pathogenesis,influencing factors and surgical prevention and treatment strategies of inguinal hernia after prostate cancer surgery [J]. Journal of Practical Oncology, 2025, 39(5): 445-449.
[13]	LYU Rui, ZHEN Linlin. Research progress on bone microenvironment-mediated drug resistance in breast cancer bone metastasis [J]. Journal of Practical Oncology, 2025, 39(5): 450-456.
[14]	LI Ji, ZHANG Maorong, YANG Zhao, WEN Hongmei, WU Fuxian, LI Yuntao. Analyses for the incidence and mortality characteristics of malignant tumors in the cancer registration areas of Kunming City,Yunnan Province in 2020 and their trend from 2016 to 2020 [J]. Journal of Practical Oncology, 2025, 39(3): 169-176.
[15]	ZHAO Entong, GUAN Xin, LI Hongyan, QIU Yunting, ZHANG Bingqiang, CHEN Mengmeng, ZOU Wei, QU Chao. SNG162 activates the estrogen signaling pathway at the membrane initiation of glioblastoma by upregulating ER-α36 expression [J]. Journal of Practical Oncology, 2025, 39(3): 177-183.

Advances in gene expression profiling of metastases from unidentified primary tumor

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments